Clostridium difficile infection

Reviews in Clinical Gerontology

Volumn 13, Issue 1, 2003, Pages 1-9

  Liang, M E K ^a,b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BACTERIAL ENZYME; CEPHALOSPORIN; CHEMOTACTIC FACTOR; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; HYDROLASE; IMMUNOMODULATING AGENT; METRONIDAZOLE; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TRIMETHOPRIM; VANCOMYCIN; VIRULENCE FACTOR;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AGED; ANAMNESIS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CHROMATOGRAPHY; CLINICAL EXAMINATION; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; DISEASE PREDISPOSITION; DRUG COST; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; FECES CULTURE; FEVER; GASTROINTESTINAL ENDOSCOPY; GLOVE; HAND WASHING; HUMAN; HYGIENE; IMMUNOTHERAPY; INTESTINE FLORA; LEUKOCYTOSIS; NURSING HOME; PATHOGENESIS; PATIENT CARE; PATIENT EDUCATION; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; REINFECTION; REVIEW; RISK FACTOR; SIGMOIDOSCOPY; TISSUE CULTURE; TOXIC MEGACOLON;

EID: 0742306335     PISSN: 09592598     EISSN: None     Source Type: Journal    
DOI: 10.1017/S095925980301311X     Document Type: Review

References (69)

1. AlSaif, Brazier N. The distribution of C difficile in the environment of South Wales. J Med Microbiol 1996; 45:133-37.
2. McFarland MV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320: 204-10.
3. Mulligan ME. General epidemiology, potential reservoirs and typing procedures. In: Rolfe RD, Finegold SM eds. Clostridium difficile - its role in intestinal disease. London: Academic Press,1988; 229-56.
4. George WL. Antimicrobial agent-associated diarrhoea in adult humans. In: Rolfe RD, Finegold SM eds. In: Clostridium difficile - its role in intestinal disease. London: Academic Press, 1988; 31-44.
5. Borriello SP, Larson HE. Antibiotic and pseudomembranous colitis. J Antimicrob Chemother 1981; 7(suppl A): 53-62.
6. Djuretic T, Ryan MJ, Fleming DM, Wall PG. Infectious intestinal diseases in elderly people. Communic Dis Rep CDR. 1996; Review 6: R107.
7. Brandt LJ, Kosche KA, Greenwald DA, Berkman D. Clostridium difficile-associated diarrhoea in the elderly. Am J Gastroenterol 1999; 94: 3262-66.
8. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-97.
9. Borriello SP, Barclay FE. An in vitro model of colonisation resistance to C difficile infection. J Med Microbiol 1986; 21: 299-309.
10. Aronsson B, Barany P, Nord CE, Nystrom B, Stenvinkel P. Clostridium-associated diarrhoea in uraemic patients. Eur J Clin Microbiol 1987; 6: 352-56.
11. Dosik GM, Luna W, Valdivicio M et al. Necrotizing colitis in patients with cancer. Am J Med 1979; 67: 646-56.
12. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and Clostridium difficile-associated diarrhoea in a cohort of hospitalised patients. J Infect Dis 1990; 162: 678-84.
13. Clabots CR, Johnson S, Olson MM, Peterson CR, Gerding DN. Acquisition of Clostridium difficile by hospitalised patients: evidence for colonised new admissions as a source of infection. J Infect Dis 1992;166: 561-67.
14. MC Farland LV, Stamm WE. Review of Clostridium difficile-associated diseases. Am J Infect Control 1986; 14: 99-109.
15. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long term care facility. Clin Infect Dis 1993; 17: 672-78.
16. Moskowitz M, Barlett JG. Recurrent pseudomembranous colitis associated with prior antibiotic therapy. Arch Intern Med 1981; 141: 663-64.
17. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17:109-13.
18. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 (suppl C): 13-19.
19. Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. A prospective study. Ann Intern Med 1974; 81: 429-33.
20. Kabbins SA, Spira TJ. Outbreaks of clindamycin colitis. Ann Intern Med 1975; 83: 830-31.
21. Impallomeni M, Galletly NP, Wort SJ, Starr JM, Rogers TR. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ 1995; 311: 1345-46.
22. Rothschild E, Rauss A, Danan G. Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. BMJ 1996; 312: 778.
23. Wistrom J, Norby SR, Myrhe EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalised patients: a prospective study. J Antimicrob Chemother 2001; 47: 43-50.
24. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998; 41(suppl C): 21-27.
25. Thompson G, Clark AH, Harre K et al. Pseudomembranous colitis after metronidazole. BMJ 1981; 282: 964.
26. Tabaqchali S, Jumaa P. Fortnightly review: Diagnosis and management of Clostridium difficile infection. BMJ 1995; 310:1375-80.
27. Gerding DN, Olson MM, Peterson LR et al. Clostridium difficile-associated diarrhoea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986; 146: 95-100.
28. de Lalla F, Privitera G, Ortisi G et al. Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital. J Antimicrob Chemother 1989; 23: 623-31.
29. Guyot A, Rawlins MDM, Barrett SP. Clarithromycin appears to be linked with Clostridium difficile-associated diarrhoea in the elderly. J Antimicrob Chemother 2000; 46: 642.
30. Wilcox MH. Clarithromycin and risk of Clostridium difficile-associated diarrhoea J Antimicrob Chemother 2001; 47: 358-59.
31. Borriello SP, Davies HA, Kamiya S, Reed PJ, Seddon S. Virulence factors of Clostridium difficile. Rev Infect Dis 1990; 12 (suppl 2S): 185-91.
32. Mulligan ME, Peterson LR, Kwok RYY, Clabots CR, Gerding DN. Immunoblots and plasmid fingerprints compared with serotyping and polyacrylamide gel electrophoresis for typing Clostridium difficile. J Clin Microbiol 1988; 26: 41-6.
33. Borriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrob Chemother 1998; 41 (suppl C): 13-19.
34. Burke GW, Wilson ME, Mehrez IO. Absence of diarrhoea in toxic megacolon complicating Clostridium difficile pseudomembranous colitis. Am J Gastroenterol 1988; 83: 304-7.
35. Borriello SP, Wilcox MH. Clostridium difficile of the gut: the unanswered questions. J Antimicrob Chemother 1998; 41 (suppl C): 67-69.
36. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-93.
37. James AH, Katzul, Dotters DJ, Rogers RG. Clostridium difficile infection in obstetric and gynaecologic patients. South Med J 1997; 90: 889-89.
38. Morris JB, Zollinger RM, Stellato TA. Role of surgery in antibiotic induced pseudomembranous colitis. Am J Surg 1990; 160: 535-39.
39. Vasishta S, Edison P, Johansen A, O'Brien D, Hosin I. Clostridium difficile diarrhoea: must we wait for toxin test results? Age Ageing 2001; 30(suppl 1): 36.
40. Roley TV, Bowman RA, Golledge CL. Usefulness of culture in the diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 1995; 32: 1360-1.
41. Kyne L, Merry C, O'Connell B, Kelly A, Keane C, O'Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999; 28: 107-13.
42. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992; 22: 85-92.
43. Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhoea and colitis. Lancet ii 1983; 1043-6.
44. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 1995; 36: 673-79.
45. Fekety R, Silva J, Buggy B, Deery HG. Treatment of antibiotic associated colitis with vancomycin. J Antimicrob Chemother 1984; 14(suppl D): 97-102.
46. Wilcox MH, Fawley WN, Settle LD, Davidson A. Recurrence of symptoms in Clostridium difficile infection - relapse or re-infection? J Hosp Infect 1998; 38: 93-100.
47. Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000; 31: 995-1000.
48. Verity P, Wilcox MH, Fawley W, Parnell P. Prospective evaluation of environmental contamination by Clostridium difficile in isolation siderooms. J Hosp Infect 2001; 49: 204-09.
49. Wilcox MH, Fawley WN. Hospital disinfectants and spore formation by Clostridium difficile. Lancet 2000; 356 (9238): 1324.
50. Bender B, Laughon B, Gaydos C, Forman M et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet 1986; 2: 11-13.
51. Garibaldi RA. Residential care and the elderly: the burden of infection. J Hosp Infect 1999; 43 (suppl): S9-18.
52. Larson E, Bobo L, Bennett R et al. Lack of caregiver hand contamination with endemic bacterial pathogens in a nursing home. Am J Infect Contr 1992; 20: 11-15.
53. Worsley MA. Infection control and prevention of Clostridium difficile infection. J Antimicrob Chemother 1998; 41(suppl C): 59-66.
54. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics Infect Control Hosp Epidemiol 1999; 20: 43-50.
55. Fekety R, Mc Farland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan ME. Recurrent Clostridium difficile diarrhoea: characteristics of and risk factors for patients enrolled in a prospective randomised double-blinded trial. Clin Infect Dis 1997; 24: 324-33.
56. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhoea. Clin Infect Dis 1996; 22: 813-18.
57. Pochapin M. The effect of probiotics in Clostridium difficile diarrhoea. Am J Gastroenterol 2000; 95(suppl 1): 11-14.
58. Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with references to Lactobacillus acidophilus and Bifidobacterium Spp. Immunol Cell Biol 2000; 78: 80-88.
59. Gorbach SI, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet ii 1987; 1519.
60. Lewenstein A, Frigerio G, Moroni M. Biological properties of SF 68. A new approach for the treatment of diarrhoeal diseases. Curr Ther Res 1979; 26: 967-1.
61. Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur J Clin Microbiol 1987; 6: 51-53.
62. Schellenberg D, Bonington A, Champion CM, Lancaster R, Webb S, Main J. Treatment of Clostridium difficile diarrhoea with Brewer's yeast. Lancet 1994; 343: 171-72.
63. Surawicz CM, Elmer GW, Speelman P, McFarlane LV, Chinn J, Van Belle G. Prevention of antibiotic associated diarrhoea by Saccharomyces Boulardii: a prospective study. Gastroenterology 1989; 96: 981-88.
64. McFarlane LV, Surawicz CM, Greenberg RN, et al. A randomised placebo-controlled trial of Saccharomyces Boulardii in combination with standard antibiotics of Clostridium difficile disease. JAMA 1994; 271: 1913-18.
65. Schwan A, Sjolin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16: 211-15.
66. Salcedo J, Keates S, Pothoulakis C et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997; 41: 366-70.
67. Ludlam H, Brown N, Sule O et al. An antibiotic policy associated with reduced risk of Clostridium difficile associated diarrhoea. Age Ageing 1999; 28: 578-80.
68. MacGowan AP, Jones EM. Back to basics in management of Clostridium difficile infections. Lancet 1998; 352: 505-56.
69. Wilcox MH. Cleaning up Clostridium difficile infection. Lancet 1996; 348: 767-68.